Immuron North American Q1 Sales Up 111% YoY
14 October 2019 - 10:30PM
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian
biopharmaceutical company focused on developing and commercializing
oral immunotherapeutics for the prevention and treatment of
gut-mediated pathogens, is pleased to announce sales results for
its commercially available, over-the-counter gastrointestinal and
digestive health supplement Travelan®, for the quarter ended
September 30, 2019, of fiscal year 2020 (Q1).
Total North American sales for Travelan® were up
111% compared to the same period last year and reached $269K* AUD,
marking a solid start to the fiscal year. In the US, Q1 sales grew
81% year on year (YoY) to $232K* AUD, primarily due to continued
expansion via our programs with Passport Health Travel Clinics,
Medique and Medico Mart. Amazon sales of Travelan through Medique
continue to remain strong. In Canada, Q1 sales reached $38K* AUD,
with Travelan now being sold in Shoppers Drug Mart, Jean Coutu, and
selected independent pharmacies in addition to Amazon.ca.
Global Immuron sales expanded by +54% YoY,
reaching $741K* AUD, as Immuron’s flagship product Travelan®
continued to grow in all geographic markets in Q1.
In Australia, Travelan® grew by 34%, achieving
sales of $458K* AUD in Q1, supported by an in-pharmacy
merchandising program and promotional catalogue activity in key
pharmacy banners. September 2019 was a record-breaking month for
Australian revenue, with sales before rebates growing to $185K*
AUD. This is the highest monthly revenue figure on record in one
market, exceeding the $182K* AUD record milestone that the USA
reported in May 2019. In August Immuron exhibited Travelan at the
HealthEd Conference in Sydney, where product was promoted to over
500 General Practitioners.
“The sales momentum for Travelan® which was
already evident in fiscal year 2019 has continued strongly into the
first quarter of fiscal year 2020 as consumer awareness of
Travelan® continues to grow,” said Dr. Gary S. Jacob, CEO of
Immuron Ltd. “During the quarter we also made two ground-breaking
announcements regarding our research collaboration with the US
Department of Defense. This included the results from a US DoD
study that showed Travelan® was cross-reactive against 71 clinical
isolates of Vibrio cholera. In addition, we recently announced a
$5.5M AUD grant with the Naval Medical Research Center to develop a
combined Campylobacter and enterotoxigenic E. coli (ETEC)-specific
anti-microbial preventative for clinical evaluation.”
Infectious diarrhea is the most common illness
reported by travelers visiting developing countries and among US
troops deployed overseas. Diarrhea morbidity decreases daily
performance, affects judgment, decreases morale and declines
operational readiness. First line treatment for infectious diarrhea
has typically been the prescription of antibiotics. Unfortunately,
in the last decade, several enteric pathogens have shown an
increased resistance to commonly prescribed antibiotics. In
addition, travelers' diarrhea is now recognized by the medical
community to result in post-infectious sequelae, including
post-infectious irritable bowel syndrome and several
post-infectious autoimmune diseases.
The global burden of diarrheal diseases
outweighs any of the more complex diseases seen in gastroenterology
clinics. Every year, there are an estimated 1.5 billion episodes of
diarrhea worldwide. These episodes result in the deaths of
approximately 2.2 million people, mostly children in developing
countries (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2699001/).
A preventative treatment that protects against enteric diseases,
specifically shigellosis, is a high priority objective for the US
Army. Shigella spp are estimated to cause 80 –165 million cases of
disease worldwide, resulting in 600,000 deaths annually and is
particularly prevalent in both sub-Saharan Africa and South
Asia.
*Unaudited gross revenue
ABOUT IMMURON:Immuron Limited
(ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical
company focused on developing and commercializing orally delivered
targeted polyclonal antibodies for the treatment of inflammatory
mediated and infectious diseases. Immuron has a novel and safe
technology platform with one commercial asset Travelan® generating
revenue. Immuron’s lead clinical candidate, IMM-124E, is presently
being developed as a drug to prevent Travelers’ Diarrhea. Immuron’s
second clinical-stage asset, IMM-529, targets Clostridium difficile
Infections (CDI), and is presently in a clinical trial in CDI
patients. These products together with the Company’s other
preclinical immunotherapy pipeline products currently under
development targeting immune-related and infectious diseases are
anticipated to meet pressing needs in the global immunotherapy
market.
For more information visit:
http://www.immuron.com
COMPANY CONTACT:
Gary S. Jacob, Ph.D.Chief Executive OfficerPh: +61
(0)3 9824 5254info@immuron.com |
AUS INVESTOR
RELATIONS: Peter TaylorNWR
CommunicationsPh: +61 (0)4 1203
6231peter@nwrcommunications.com.au |
USA INVESTOR RELATIONS: Dave Gentry -
CEO RedChip Companies, Inc. US Ph: +1 (407) 491 4498
dave@redchip.com |
About
Travelan®Travelan® is an orally administered
passive immunotherapy that prophylactically reduces the likelihood
of contracting travelers’ diarrhea. Travelan® is a highly purified
tabletized preparation of hyper-immune bovine antibodies and other
factors, which when taken with meals bind to diarrhea-causing
bacteria and prevent colonization and the pathology associated with
travelers’ diarrhea. In Australia, Travelan® is a listed medicine
on the Australian Register for Therapeutic Goods (AUST L 106709)
and is indicated to reduce the risk of Travelers’ Diarrhea, reduce
the risk of minor gastro-intestinal disorders and is antimicrobial.
In Canada, Travelan® is a licensed natural health product (NPN
80046016) and is indicated to reduce the risk of Travelers’
Diarrhea. In the U.S., Travelan® is sold as a dietary supplement
for digestive tract protection.
About Travelers’
DiarrheaTravelers’ diarrhea is a gastrointestinal
infection with symptoms that include loose, watery (and
occasionally bloody) stools, abdominal cramping, bloating, and
fever, Enteropathogenic bacteria are responsible for most cases,
with enterotoxigenic Escherichia coli (ETEC) playing a dominant
causative role. Campylobacter spp. are also responsible for a
significant proportion of cases. The more serious infections with
Salmonella spp., the bacillary dysentery organisms belonging to
Shigella spp. and Vibrio spp. (the causative agent of cholera) are
often confused with travelers’ diarrhea as they may be contracted
while travelling and initial symptoms are often
indistinguishable.
FORWARD-LOOKING STATEMENTS:This
press release may contain “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, each as amended.
Such statements include, but are not limited to, any statements
relating to our growth strategy and product development programs
and any other statements that are not historical facts.
Forward-looking statements are based on management’s current
expectations and are subject to risks and uncertainties that could
negatively affect our business, operating results, financial
condition and stock value. Factors that could cause actual results
to differ materially from those currently anticipated include:
risks relating to our growth strategy; our ability to obtain,
perform under and maintain financing and strategic agreements and
relationships; risks relating to the results of research and
development activities; risks relating to the timing of starting
and completing clinical trials; uncertainties relating to
preclinical and clinical testing; our dependence on third-party
suppliers; our ability to attract, integrate and retain key
personnel; the early stage of products under development; our need
for substantial additional funds; government regulation; patent and
intellectual property matters; competition; as well as other risks
described in our SEC filings. We expressly disclaim any obligation
or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in our expectations or any changes in events, conditions or
circumstances on which any such statement is based, except as
required by law.
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Apr 2024 to May 2024
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From May 2023 to May 2024